Sacituzumab, as a therapeutic, is an antibody–drug conjugate (ADC) composed of a humanized monoclonal antibody targeted against trophoblast cell-surface antigen 2 (Trop-2) conjugated to a potent cytotoxic payload. Structurally, the antibody component belongs to the immunoglobulin G1 kappa (IgG1κ) subclass and has a molecular weight of approximately 150 kilodaltons (kDa). It consists of two identical heavy chains and two identical light chains linked by disulfide bridges, forming the characteristic Y-shaped configuration typical of immunoglobulins. The antibody is produced through recombinant DNA technology in mammalian expression systems, ensuring proper folding, glycosylation, and immunoglobulin stability.
The Trop-2-binding regions of Sacituzumab are located in the variable domains of its heavy (VH) and light (VL) chains, which contain complementarity-determining regions (CDRs) that confer high-affinity binding to a specific extracellular epitope on the Trop-2 glycoprotein. Trop-2 is a transmembrane calcium signal transducer involved in cellular proliferation and adhesion processes. The antibody’s recognition of Trop-2 leads to receptor-specific binding and internalization via endocytosis.
The Fc (fragment crystallizable) portion contributes to molecular stability and longevity through neonatal Fc receptor (FcRn) recycling.
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.
Have a product or application question? Consult our FAQs or contact us.
